# A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients

> **NCT06666283** · PHASE1 · RECRUITING · sponsor: **Alebund Pharmaceuticals** · enrollment: 18 (estimated)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** AP303 150μg
- **DRUG:** Placebo 150μg

## Key facts

- **NCT ID:** NCT06666283
- **Lead sponsor:** Alebund Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-27
- **Primary completion:** 2025-09-25
- **Final completion:** 2025-09-25
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06666283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06666283, "A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06666283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*